Thermo Fisher Scientific Inc. $TMO Stock Acquired by Vise Technologies Inc.

Vise Technologies Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 48.1% in the third quarter, Holdings Channel reports. The firm owned 13,494 shares of the medical research company’s stock after buying an additional 4,382 shares during the quarter. Vise Technologies Inc.’s holdings in Thermo Fisher Scientific were worth $9,109,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Investment Partners LTD. lifted its position in Thermo Fisher Scientific by 12.5% during the 3rd quarter. Investment Partners LTD. now owns 1,597 shares of the medical research company’s stock worth $1,079,000 after acquiring an additional 178 shares during the period. Cidel Asset Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 1.9% in the third quarter. Cidel Asset Management Inc. now owns 2,224 shares of the medical research company’s stock valued at $1,501,000 after purchasing an additional 41 shares during the period. Summit Global Investments raised its stake in shares of Thermo Fisher Scientific by 72.3% during the third quarter. Summit Global Investments now owns 2,178 shares of the medical research company’s stock worth $1,471,000 after purchasing an additional 914 shares during the last quarter. MGO One Seven LLC raised its stake in shares of Thermo Fisher Scientific by 26.3% during the third quarter. MGO One Seven LLC now owns 7,745 shares of the medical research company’s stock worth $5,229,000 after purchasing an additional 1,615 shares during the last quarter. Finally, Americana Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.7% during the third quarter. Americana Partners LLC now owns 81,349 shares of the medical research company’s stock worth $54,914,000 after purchasing an additional 566 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on TMO. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $723.00 to $756.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Barclays raised their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada lifted their target price on shares of Thermo Fisher Scientific from $580.00 to $730.00 and gave the company a “sector perform” rating in a report on Thursday, October 22nd. Finally, BMO Capital Markets lowered shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $689.10.

Thermo Fisher Scientific Stock Down 0.0%

Thermo Fisher Scientific stock opened at $696.78 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.41. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $711.85. The company has a market cap of $257.63 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84. The stock’s 50 day moving average price is $654.87 and its 200 day moving average price is $552.94.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The firm had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business posted $5.79 earnings per share. Thermo Fisher Scientific’s revenue was up 9.1% compared to the same quarter last year. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 76,199 shares of company stock worth $45,896,780. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.